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Poststroke Neurological Improvement Within 7 Days Is
Associated With Subsequent Deterioration
Stella Aslanyan, MD; Christopher J. Weir, PhD; S. Claiborne Johnston, MD, PhD;
Kennedy R. Lees, MD, FRCP; for the GAIN International Steering Committee and Investigators
Background and Purpose—Improvement in the National Institutes of Health Stroke Scale (NIHSS) 24 hours after stroke
has been associated with subsequent neurological deterioration. We hypothesized that a similar association would be
apparent for events occurring after 7 days, when acute changes from edema and herniation are less common. We
evaluated the degree of NIHSS improvement at 7 days (recovery) as a predictor of subsequent neurological deterioration
from day 7 to day 90.
Methods—We studied all patients of the Glycine Antagonist (gavestinel) In Neuroprotection (GAIN) International Trial
with ischemic stroke alive at day 7, excluding patients with hemorrhagic events and deaths from nonstroke-related
causes. The GAIN International Trial was a randomized, double-blind, placebo-controlled, and parallel-group trial;
because the study drug had no effect on stroke outcome, treatment groups were combined for this analysis. Neurological
deterioration was assessed by the combined measure, including: (1) stroke-related events recorded as “serious adverse
events,” (2) recurrent stroke recorded on a separate case report form, and (3) any NIHSS worsening.
Results—Among 1187 patients included, 25% had 65% recovery. Deterioration was more prevalent in the group with
65% early recovery (15.5% versus 10.3%; P0.01). Logistic regression modeling indicated that recovery was
associated with subsequent neurological deterioration (odds ratio, 1.2; 95% CI, 1.1 to 1.3, per 10% recovery) after
adjusting for age, NIHSS at 7 days, and stroke subtype.
Conclusions—Substantial neurological recovery at 7 days is associated with subsequent neurological deterioration.
(Stroke. 2004;35:2165-2170.)
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Several studies have suggested that short-term stroke riskafter transient ischemic attack (TIA) is greater than after
stroke. For example, in a cohort of patients diagnosed with
TIA in the emergency department, 10.5% had a stroke during
the first 3 months after the index event.1 Stroke risk after a
completed stroke has been reported to be lower in clinical
trials, with recurrence rates ranging from 3% to 6% at 6
months.2,3 Observational studies suggest stroke recurrence
rates of 3% to 6% at 1 month4–6 and 7% at 3 months.7 Direct
comparisons of those studies are confounded by differences
in study design.
The recurrent stroke rate within 3 months was substantially
higher after hemispheric TIA than after completed stroke
(20.1% versus 2.3%) in the medical arm of the North
American Symptomatic Carotid Endarterectomy Trial.8 Pa-
tients of the National Institute of Neurological Diseases and
Stroke t-PA Trial9 and the Trial of ORG 10172 in Acute
Stroke Treatment (TOAST)10 with TIA were at greater risk of
subsequent neurological deterioration, defined as worsening
of National Institutes of Health Stroke Scale (NIHSS)11 score
from day 1 to day 90 resulting from causes other than
hemorrhage, than those with completed stroke.12,13 Further,
the risk of subsequent neurological deterioration extended to
acute substantial but incomplete recovery of 50% to 100% in
NIHSS at 24 hours from baseline.12,13
In studies evaluating a 24-hour time point for recovery,
early changes attributable to factors other than new ischemia
could account for subsequent deterioration, including wors-
ening edema and reperfusion injury. This should be less
evident 1 week after the initial stroke; deterioration after
the first week may be more indicative of new ischemia. In
fact, patients with reversible ischemic neurological deficit14
with symptom resolution by 3 weeks and TIA had similar
subsequent stroke event rates (38%) in contrast to patients
with completed stroke (23%) during the mean follow-up of 2
years.15 Further, patients with TIA and those in whom
symptoms resolve within 7 days have significantly higher
rates of subsequent ischemic stroke compared with those with
a longer duration of initial symptoms.16 These time factors
and definitions of complete symptom resolution in distin-
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guishing between TIA, reversible neurological deficits, and
stroke are arbitrary.13,15,17
In this study, we investigated whether the degree of
ischemic stroke recovery at 7 days is associated with risk of
neurological deterioration occurring between days 7 and 90
after stroke. We analyzed data from the Glycine Antagonist
(gavestinel) In Neuroprotection (GAIN) International Trial18
to test the hypothesis that stroke recovery at 7 days is
associated with increased risk of subsequent neurological
deterioration.
Subjects and Methods
GAIN International was a multicenter, randomized, double-blind,
placebo-controlled, parallel-group trial conducted to test the effec-
tiveness of gavestinel for acute stroke treatment. The trial was
approved by regulatory and ethics committees of each participating
institution. Written or witnessed verbal informed consent was ob-
tained for all patients. The trial included previously independent
patients with symptoms of acute stroke who were 18 years of age
and who presented within 6 hours of stroke onset. Subjects had limb
weakness (drift within 10 s for the arm or 5 s for the leg; if mild, both
should have been affected). Exclusion criteria were reported previ-
ously.18 Standard stroke care was accompanied by gavestinel or
placebo administration. None of the patients received thrombolytic
therapy. The diagnoses were confirmed by imaging. Gavestinel had
no effect on stroke outcome or occurrence of serious adverse events.
For this study, we selected patients with confirmed cerebral ischemia
who were alive at 7 days and had NIHSS recorded at 7 days
(postrandomization NIHSS was not recorded before 7 days in this
trial) from both treatment groups combined.
Our primary outcome measure was “neurological deterioration”
from day 7 to day 90. It included (1) “stroke-related events” after day
7 (serious adverse events related to a new ischemic event or to the
original stroke, such as stroke deterioration, evolution, extension,
progression, or neurological damage or deterioration resulting from
the original stroke); (2) “recurrent stroke” after day 7 (recorded on a
separate case report form as one of the prespecified events common
to stroke patients); and (3) NIHSS worsening (dichotomized as
“worse, by at least 1 point” versus “no change or better” from day 7
to day 90). The main clinical interest in this study is the risk of
stroke-related events. Considering the post hoc nature of our study
and the difficulties of assessing the cause and extent of poststroke
deterioration (and therefore under-reporting of stroke events), the
combined neurological deterioration was used as a surrogate. Stroke
recovery was assessed by NIHSS percentage change from baseline to
day 7.
TABLE 1. Comparison of Groups With and Without >65% Recovery and Neurological Deterioration
Variables
65% Recovery Neurological Deterioration
With (n303) Without (n884) P * With (n138) Without (n1049) P *
Age (y), meanSD 6713 7012 0.0001 7213 6912 0.0003
Gender, male (%) 58 57 0.6 54 57 0.5
Treatment, gavestinel (%) 49 48 0.8 46 49 0.3
Systolic BP, meanSD 15727 15927 0.1 15727 15827 0.6
Diastolic BP, meanSD 8715 8615 0.2 8615 8715 0.6
White cell count, 109/L, meanSD 8.82.9 8.92.8 0.5 8.72.6 8.92.8 0.6
Risk factors (%)
Atrial fibrillation 21 27 0.04 33 25 0.04
Hypertension 46 55 0.005 49 53 0.4
Diabetes 15 17 0.3 17 17 0.8
Hypercholesterolemia 24 22 0.5 20 23 0.3
Current smoker 26 21 0.1 20 23 0.3
Alcohol consumption 9.9 10 0.9 9.4 10 0.7
Previous myocardial infarction 11 14 0.1 14 13 0.7
Previous stroke 14 15 0.6 12 12 0.9
OCSP classification (%)
Lacunar 32 18 0.0001 15 22 0.3
Partial anterior 40 37 40 38
Total anterior 21 29 40 34
Posterior 3.6 4.2 3.6 4.1
NIHSS score, meanSD†
Baseline 9.55.0 (12-9-6) 136.0 (17-12-8) 0.0001 136.0 (17-12-8) 126.0 (16-11-7) 0.09
7 days 1.51.5 (2-1-0) 127.0 (17-11-6) 0.0001 9.98.7 (17-8-2) 9.07.4 (14-7-3) 0.7
90 days 1.33.6 (1-0-0) 8.38.3 (12-6-2) 0.0001 1514 (23-12-3) 5.35.7 (9-3-1) 0.0001
Neurological deterioration 15 10 0.01 100 0
65% recovery 100 0 34 24 0.01
*2 test or t test.
†Upper quartile-median-lower quartile.
BP indicates blood pressure.
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Patients who died as a result of causes other than stroke-related
events were excluded, as were patients who had a hemorrhage from
day 7 to day 90, to investigate the deterioration purely because of the
ischemic neurological events.
Statistical Analyses
Means with SDs (for continuous variables) and percentages (for
categorical variables) of the baseline factors and NIHSS scores were
compared between groups with and without recovery at 7 days and
between groups with and without deterioration. Stratification of
recovery was based on the best cut point in sensitivity analysis for
predicting subsequent neurological deterioration.
Logistic regression was used to investigate the effect of percentage
of recovery at 7 days as a continuous variable on neurological
deterioration, in univariate analyses, and after adjusting for prognos-
tic factors (NIHSS at 7 days, age and stroke subtype by Oxfordshire
Community Stroke Project [OCSP]19 clinical classification). Using
ANOVA, we compared these models with generalized additive
modeling to identify a nonlinear relationship of any form between
degree of early recovery and outcome. In sensitivity analysis, we
used cut points from 0% to 100% by 5% intervals in degree of
recovery to predict neurological deterioration after correcting for
prognostic factors. The best cut point was chosen on the basis of the
highest odds ratio (OR).
Patients were stratified by the quartiles of NIHSS at 7 days. The
association between stroke recovery dichotomized by the best cut
point and neurological deterioration was investigated in each sub-
group. The SAS System V8 and S-PLUS 6.0 statistical software were
used for analysis.
Results
Of 1455 patients, 1313 were alive at 7 days. Of these, 1 had
missing values for NIHSS at 7 days, 3 had a hemorrhagic
stroke, and 122 (9.3%) died from noncerebrovascular causes.
Thus, our sample comprised 1187 patients.
The best cut point for predicting neurological deterioration
was 65% recovery from baseline. Patients with recovery
65% were younger, had lower rates of atrial fibrillation,
hypertension, and total anterior circulation infarction, and had
higher rates of lacunar stroke compared with patients without
recovery (Table 1). They had lower NIHSS scores at baseline,
at 7 and 90 days, and had higher rates of neurological
deterioration. Patients with deterioration were older, had
higher rates of atrial fibrillation and recovery, and higher
NIHSS scores at 90 days (Table 1).
Considering the composite nature of our main outcome
measure of neurological deterioration, Figure 1 presents the
number of events and the overlap of stroke-related events,
recurrent stroke, and NIHSS worsening. Thus, 11 cases of
only stroke-related events, 4 cases of only recurrent stroke,
and 7 cases of stroke-related events and recurrent stroke did
not correspond to the NIHSS worsening definition. In 79
patients, the cause of NIHSS worsening was not identified
specifically. Figure 2 presents NIHSS change from day 7 to
90 in patients, with the primary outcome of neurological
deterioration.
Table 2 presents the ORs per additional 10% recovery
predicting neurological deterioration. After adjusting for age,
NIHSS at 7 days, and stroke subtype, recovery was associated
with neurological deterioration; each 10% increase in recov-
ery was associated with 16% increase in the odds of neuro-
logical deterioration (95% CI, 6% to 28%). There was no
significant difference between logistic and generalized addi-
tive models, indicating no substantial nonlinear relationship
between percentage recovery and neurological deterioration.
Along with age, NIHSS at 7 days predicted neurological
deterioration (Table 2). In view of this strong association
between NIHSS at 7 days and at outcome, we stratified the
sample by quartiles of NIHSS at 7 days. In the first group
(NIHSS 0 to 2; n274), 88% of patients had a 65%
recovery. In the second group (NIHSS 3 to 8; n369), only
17% of patients had a 65% recovery. The other 2 groups
combined (n544) did not have any case of recovery 65%
(Figure 3). Table 3 presents the rates of neurological deteri-
oration in patients stratified by65% recovery and NIHSS at
7 days. In the first subgroup, there was a nonsignificant trend
toward patients with 65% recovery having a higher rate of
subsequent deterioration (14% versus 3%; P0.07), which
Figure 1. Composition of primary outcome measure of neuro-
logical deterioration.
Figure 2. Distribution of NIHSS change from day 7 to day 90 for
patients with primary outcome measure of neurological
deterioration.
TABLE 2. Variables Predicting Neurological Deterioration
Regression
Modeling Variables OR (95% CI) P
Univariate Recovery, per additional 10% 1.0 (1.0–1.01) 0.2
Multiple* Recovery, per additional 10% 1.2 (1.1–1.3) 0.0009
Age, per additional year 1.0 (1.0–1.0) 0.002
7-day NIHSS, per additional point 1.1 (1.0–1.1) 0.007
*Recovery, age, 7-day NIHSS, and stroke subtype are included.
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was confirmed in the second subgroup (19% versus 7%;
P0.004). After correcting for age, stroke subtype, and
NIHSS at 7 days, 65% recovery was associated with
neurological deterioration in the entire sample (OR, 2.9; 95%
CI, 1.7 to 5.0) and in the second subgroup (OR, 3.7; 95% CI,
1.4 to 9.6) but not in the first (OR, 3.6; 95% CI, 0.4 to 30.0).
In additional sensitivity analysis, including all patients
alive at 7 days (n1313), recovery and absence of neuro-
logical deterioration were associated in univariate analysis
(OR, 0.9; 95% CI, 0.9 to 0.9 per 10% recovery). However,
after correcting for prognostic factors, findings were con-
sistent with those of the main analysis, recovery being
associated with neurological deterioration (OR, 1.1; 95%
CI, 1.1 to 1.2).
Discussion
We found a strong linear association (on the logit scale)
between high levels of early stroke recovery and subsequent
neurological deterioration after adjusting for age, NIHSS at 7
days and stroke subtype. There was no difference in the
recovery and deterioration between randomized treatment
groups, justifying the combination of both groups.
We used a composite outcome measure for neurological
deterioration. However, when analyzing the components
separately (Figure 1), the ORs were similar in direction and
significance for stroke-related events and NIHSS worsening
(results are not presented for simplicity), suggesting that the
choice of the primary outcome measure was appropriate.
The best cut point of early recovery for predicting neuro-
logical deterioration was 65%; it had a higher OR in both
univariate and corrected models predicting the neurological
deterioration and its components. Dichotomizing recovery in
this way renders it easier to interpret and aids comparison
with previous studies.12,13 The relationship between substan-
tial recovery by 7 days and later NIHSS worsening found in
our study supports the results published for recovery by 24
hours12,13 and 7 days.16 Complete symptom resolution at day
112,13 and day 7 does not appear to be required to identify a
patient with greater risk of subsequent neurological
deterioration.
After 7 days, the cause of deterioration is less likely to be
stroke progression or evolution and more likely to be a new
ischemic event. However, documentation of deterioration in a
clinical trial setting might not relate directly to the underlying
pathophysiological phenomena. Elevated risk of new ische-
mic stroke after initial early recovery from stroke could be an
indicator of overall pathophysiological instability: brain tis-
sue being at risk of recurrent ischemic event.
To be able to speculate further on the underlying process,
we conducted a subgroup analysis by TOAST classification.10
The association between 65% recovery and neurological
deterioration was stronger in patients with large-vessel
atherothromboembolic stroke (n327; OR, 4.3; 95% CI, 1.2
to 15.1), confirming that this subtype predisposes to stroke
events and makes recovery less stable because of rethrombo-
ses. There was no statistically significant association in
patients with cardioembolic stroke (n331; OR, 1.9; 95% CI,
0.7 to 5.2) or with lacunar stroke (n184; OR, 1.3; 95% CI,
0.3 to 4.7). However, ORs presented overlap with each other,
indicating that small sample size might contribute to absence
of association. Our results confirm that large-vessel athero-
thrombosis can predispose to stroke events and make recov-
ery less stable because of rethromboses. Cardioembolic
strokes may have spontaneous or therapy-induced total or
partial thrombolysis and might rethrombose, whereas patients
with lacunar stroke have steady slow recovery. Apart from
limited sample size, we may have failed to find supportive
evidence in the subgroup with cardioembolic strokes because
of no thrombolytic treatment and exclusion of patients who
died from causes other than stroke-related events who tended
to have greater cardiac pathology.
In subgroup analyses, the association was the strongest in
the group with a 7 day NIHSS of 3 to 8. No evidence of this
Figure 3. Recovery of patients stratified
by 7 day NIHSS.
TABLE 3. Neurological Deterioration Rates in Patients With
and Without >65% Recovery Stratified by 7-Day NIHSS
65% Recovery
7-Day NIHSS With Without P All
0–2 14% (35/241) 3.0% (1/33) 0.07 13% (36/274)
3–8 19% (12/62) 7.5% (23/307) 0.004 9.5% (35/369)
9–36 — (0/0)* 12% (67/544) —* 12% (67/544)
P 0.3 0.03 0.3
All 15% (47/303) 10% (91/884) 0.01 12% (138/1187)
*Not calculated because none of the patients had 65% recovery.
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in the group with an NIHSS of 0 to 2 might be because of
small sample size with a univariate analyses P value of 0.07
(Table 3) and wide OR CI after correcting for prognostic
factors. Other reasons for presented discrepancies might be
the higher rate of lacunar strokes in the group with an NIHSS
of 0 to 2 compared with the group with an NIHSS of 3 to 8
(39% versus 28%; P0.005), which have a steadier course of
recovery. However, there was no statistically significant
interaction between lacunar strokes and 65% recovery
(P0.09).
Although this is the third study to find an association
between early recovery and subsequent risk of neurological
deterioration, none of the published studies have included a
large number of patients with substantial early recovery or
have investigated recovery at 7 days. Further studies, which
have available recordings of NIHSS at 24 hours and 7 days,
are necessary to investigate the relative prognostic values of
acute (24 hours) and early (7 days) stroke recovery. The
clinical implications are unknown. Secondary prevention
interventions should commence in all patients but especially
in those with early recovery, regardless of the timing of event
resolution and its completeness. We cannot recommend any
specific measures of prevention from our observational study.
Prospective studies, such as the Fast Assessment of Stroke
and TIA to prevent Early Recurrence (FASTER) Trial, will
examine this issue further, administering preventive treatment
with aspirin and clopidogrel or with aspirin and simvastatin
within 12 hours of TIA or acute stroke.20 The Prevention
regimen For Effectively avoiding Second Stroke (ProFESS)
Trial will investigate the secondary prevention of telmisartan
combined with aspirin and dipyridamole or aspirin and
clopidogrel, with treatment initiation within 90 days of index
stroke.21 Post hoc subset analysis of those trials may reveal
differences in therapeutic benefits apparent in those with
early recovery but not in those without recovery because the
risk of new ischemia may be greater in the former. It might be
beneficial to compare the appropriate groups of these 2 trials
in combined post hoc analysis to discriminate between early
and late initiation of secondary prevention.
Similar results from sensitivity analyses of the sample
including all patients alive at day 7 after correction for age
and NIHSS scores at day 7 indicate that we did not introduce
a bias by excluding patients who died from causes other than
stroke-related events. The opposite relationship found in
univariate analyses was expected because patients who might
die from other causes probably will not have good recovery at
7 days because they will have higher comorbidity, older age,
and more severe stroke.
Our study experienced some limitations. First, patients
with very early improvement of stroke symptoms were
excluded from the trial, and those cases with early recovery
that were included may be more unstable than those seen in
general practice. Second, we might have introduced a mea-
surement bias because new ischemic events may go unno-
ticed in the nonrecovery group, in which a neurological
deficit may mask the new event. However, this bias is
clinically unimportant to the patient. Furthermore, the asso-
ciation persisted after adjustment for and stratification by
neurological condition at 7 days. Finally, postrandomization
NIHSS was not recorded before 7 days in the GAIN Trial; we
could not directly compare the effect of recovery at 24 hours
and at 7 days on neurological deterioration.
“Regression to the mean” can bias our results on NIHSS
worsening. This is a statistical phenomenon that occurs when
there is nonrandom sampling from a population (in this case,
patients with recovery at 7 days) and when 2 or more
measures are correlated imperfectly (in this case, 3 measure-
ments of NIHSS score: at baseline, at 7 days, and at 3
months). However, separate analyses of the components of
neurological deterioration showed a similar association for
NIHSS worsening and stroke-related events; the association
between stroke-related events and recovery could not be
explained by regression to the mean. The mean NIHSS values
at 7 days in the 65% recovery group may also suggest that
any NIHSS worsening might be simply attributable to ran-
dom variability or measurement error; the scores are so low
that they can only rise. However, the associations between
early recovery and subsequent deterioration were strongest in
the group with an NIHSS score of 3 to 8 at 7 days, in which
this measurement error should not be an issue.
In conclusion, substantial neurological recovery at 7 days
was associated with subsequent neurological deterioration in
this cohort study after adjusting for age, NIHSS at 7 days, and
stroke subtype.
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